Cardiff Oncology to Host Key Opinion Leader Discussion Focusing on First-Line RAS-mutated Metastatic Colorectal Cancer

Core Insights - Cardiff Oncology, Inc. is hosting a KOL webinar to discuss the treatment landscape for first-line RAS-mutated metastatic colorectal cancer (mCRC) on March 25, 2026 [1] - The webinar will feature key opinion leaders Scott Kopetz, M.D., Ph.D., FACP and Heinz-Josef Lenz, M.D., alongside interim CEO Mani Mohindru, focusing on the clinical data of onvansertib and its potential in mCRC management [2] Company Overview - Cardiff Oncology is a clinical-stage biotechnology company focused on developing innovative cancer treatments through PLK1 inhibition, with its lead asset onvansertib currently in a Phase 2 trial for first-line treatment of RAS-mutated mCRC [6] - Onvansertib targets a significant patient population with high unmet needs and is also being investigated in other PLK1-driven cancers, demonstrating robust clinical activity in challenging tumors [6] Key Opinion Leaders - Scott Kopetz, M.D., Ph.D., FACP, is a recognized leader in colorectal cancer research, focusing on new treatment approaches for molecularly defined colorectal cancers and has led numerous clinical studies [3] - Heinz-Josef Lenz, M.D., is a professor with a focus on molecular mechanisms of cancer and biomarker-driven treatment approaches, holding leadership roles in national oncology research initiatives [4] Webinar Details - Interested parties can register for the live webcast on Cardiff Oncology's website, with a replay available post-discussion [5]